Antiplatelet Agent Reversal Is Unnecessary in Blunt Traumatic Brain Injury Patients Not Requiring Immediate...

Area of Science:

• Neuroscience
• Trauma Surgery
• Hematology

Background:

• Traumatic brain injury (TBI) with acute traumatic intracerebral hemorrhage (TICH) in patients on antiplatelet agents presents a challenge.
• The efficacy of reversing antiplatelet effects with platelet transfusions in TBI patients is debated.

Purpose of the Study:

• To investigate if emergent platelet transfusion impacts hemorrhage expansion, mortality, or neurosurgical intervention in TBI patients with TICH.
• To clarify the role of platelet transfusions in managing antiplatelet-induced coagulopathy in TBI.

Main Methods:

• Retrospective review of adult blunt TICH patients (age ≥16) over 4 years.
• Exclusion of patients with penetrating TBI, warfarin use, or immediate operative needs.
• Comparison of outcomes between patients receiving platelet transfusion (reversal group) and those not (no reversal group).

Main Results:

• Platelet transfusion did not significantly alter TICH extension (26% vs 21%, P = .71).
• No significant difference in TBI-specific mortality (9% vs 13%, P = .45) was observed.
• Need for ICP monitoring, burr holes, or craniotomy remained similar between groups.

Conclusions:

• Emergent platelet transfusion is not indicated for blunt TBI patients on chronic antiplatelet therapy without immediate need for craniotomy.
• Current evidence suggests platelet transfusion does not improve outcomes in this specific patient cohort.